Proton pump inhibitor versus histamine-2 receptor antagonist for prevention of bleeding after ESD in patients on low-dose aspirin therapy (PH-BEST study)

Proton pump inhibitor versus histamine-2 receptor antagonist for prevention of bleeding after ESD in patients on low-dose aspirin therapy (PH-BEST study) - PH-BEST study

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000011915

Enrollment

260

Registered

2013-09-30

Start date

2013-09-20

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients with gastric adenoma or early gastric cancer receiving low-dose aspirin

Interventions

rabeprazole sodium famotidine

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Patients of 20 years or elder 2. Patients taking LDA more than 4 weeks 3. Patients with high risk of thrombosis 4. Patients who are recommended taking LDA by thier doctor or specialist 5. Patients who will take LDA at least 8 weeks 6. Patients with gastric lesion which can be resected by en-bloc fashion 7. Patients with gastric adenoma or early gastric cancer which correspond to standard indication or expanded indication 8. Patients with performance status 0 to 2

Exclusion criteria

Exclusion criteria: 1. Patients with allergy for rabeprazole and famotidine 2. Patients taking anticoagulants 3. Patients with active peptic ulcer 4. Patients on dialysis 5. Patients under treatment of atazanavir sulfate 6. Patients who have other malignant neoplasms or serious disease

Design outcomes

Primary

Measure	Time frame
Incidence of post-ESD ulcer bleeding	—

Secondary

Measure	Time frame
Healing rate of ulcers at 8 weeks after ESD	—

Countries

Japan

Contacts

Public ContactShusei Fukunaga

Osaka City University Graduate School of Medicine Department of Gastroenterology

m1156849@med.osaka-cu.ac.jp06-6645-3811

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026